No Data
Stifel Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $26
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $25
We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
Evercore ISI Cuts Price Target on Cabaletta Bio to $15 From $25, Keeps Outperform Rating